Multimodal Neurotherapeutics Program
Overview
This program supports research that seeks to develop and refine multimodal or combination non-invasive neuromodulation therapies; identify and validate targets for novel interventions using such modalities; identify functional biomarkers associated with novel targets; and further elucidate brain-behavior relationships. The overall goal is to advance neurotherapeutics for major mental disorders and clinical dimensions of psychopathology (RDoC) through a “non-siloed,” personalized medicine approach with an emphasis on the synergistic effects of combined approaches.
Areas of Emphasis
- Early-phase (Proof of Mechanism) studies to test and analyze novel multimodal interventions and their network and/or clinical targets
- Proof of Concept clinical trials to demonstrate target engagement, safety, and early signs of efficacy of promising multimodal interventions
- Studies to evaluate potential biomarkers, including engagement of relevant cognitive-behavioral (e.g., emotional reactivity, neurocognitive performance) and brain-related components, using fMRI, electrophysiology, etc. to demonstrate target engagement and related biological, behavioral, or cognitive effects
- Treatment studies integrating biomarkers with traditional endpoints to validate the utility of putative surrogate markers of treatment response
- Studies to predict treatment response and facilitate individualized treatment strategies
- Studies of intervention development that seek to mitigate adverse effects of multimodal interventions
- Studies to identify mechanisms of multimodal effects and their association with aspects of behavior or cognition
Contact
Lizzy Ankudowich, Ph.D.
Program Chief
6001 Executive Boulevard
301-480-8187, lizzy.ankudowich@nih.gov